Flagship Ventures Fund IV-Rx, L.P.
CIK 1590973 · last filed 2022-03-18
Flagship Ventures Fund IV-Rx, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 5 companies since 2016. Across all open-market trades the lifetime net is −$77.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.04B across reported positions. The firm reports its address in Cambridge, MA. 33 SEC filings were submitted jointly with Flagship Ventures Fund IV General Partner LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Axcella Health Inc. (AXLA) Delisted | 10%+ Owner | 81,433 | $0.40 | $32.6K | $172.42M | 2 | 2022-03-18 |
| Evelo Biosciences, Inc. (EVLO) Delisted | 10%+ Owner | 39,798 | $0.00 | $4 | $33.60M | 2 | 2021-02-04 |
| MRNA | 10%+ Owner | 21,986,399 | $183.97 | $4.04B | -$313.86M | 2 | 2020-05-26 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | 10%+ Owner | 5,789,414 | $0.08 | $480.5K | $0 | 1 | 2018-07-23 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 83,866 | $0.00 | $34 | $30.00M | 1 | 2016-07-07 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-13 | — | Notice (144) | −55,925 | -$12.9K | EDGAR |
| 2022-03-18 | Axcella Health Inc. (AXLA) Delisted | Buy (P) | +37,916,226 | $72.42M | EDGAR |
| 2021-02-04 | Evelo Biosciences, Inc. (EVLO) Delisted | Buy (P) | +1,040,000 | $15.60M | EDGAR |
| 2020-05-26 | MRNA | Sell (S) | −4,000,000 | -$272.88M | EDGAR |
| 2019-12-11 | MRNA | Mixed | −48,357,875 | -$40.98M | EDGAR |
| 2019-05-15 | Axcella Health Inc. (AXLA) Delisted | Mixed | +60,339,740 | $100.00M | EDGAR |
| 2018-07-23 | Rubius Therapeutics, Inc. (RUBY) Delisted | Conv (C) | +299,668,734 | $0 | EDGAR |
| 2018-05-15 | Evelo Biosciences, Inc. (EVLO) Delisted | Mixed | +59,613,572 | $18.00M | EDGAR |
| 2016-07-07 | Syros Pharmaceuticals, Inc. (SYRS) Delisted | Mixed | +27,559,944 | $30.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.